Healthcare provider profile · identity verified

Meagan Schaeffner

Internal Medicine · LEXINGTON, KY · NPI 1043672686

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	306	75
Fluticasone Propionate	Fluticasone Propionate	211	38
Gabapentin	Gabapentin	171	25
Famotidine	Famotidine	144	29
Bupropion Xl	Bupropion Hcl	132	18
Amlodipine Besylate	Amlodipine Besylate	130	26
Tamsulosin Hcl	Tamsulosin Hcl	130	27
Rosuvastatin Calcium	Rosuvastatin Calcium	115	27
Lisinopril	Lisinopril	111	28
Omeprazole	Omeprazole	98	16
Levothyroxine Sodium	Levothyroxine Sodium	88	16
Pregabalin	Pregabalin	88	12
Pantoprazole Sodium	Pantoprazole Sodium	87	16
Trazodone Hcl	Trazodone Hcl	85	12
Albuterol Sulfate Hfa	Albuterol Sulfate	75	14
Carvedilol	Carvedilol	72	16
Chlorthalidone	Chlorthalidone	70	18
Hydrochlorothiazide	Hydrochlorothiazide	66	14
Mounjaro	Tirzepatide	66	suppressed
Azelastine Hcl	Azelastine Hcl	61	suppressed
Duloxetine Hcl	Duloxetine Hcl	60	16
Trulicity	Dulaglutide	59	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	58	suppressed
Losartan Potassium	Losartan Potassium	56	15
Ondansetron Odt	Ondansetron	54	11
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	52	suppressed
Ketoconazole	Ketoconazole	52	suppressed
Sertraline Hcl	Sertraline Hcl	52	suppressed
Jardiance	Empagliflozin	44	suppressed
Metformin Hcl Er	Metformin Hcl	41	suppressed
Repatha Sureclick	Evolocumab	40	suppressed
Alendronate Sodium	Alendronate Sodium	39	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	39	11
Metformin Hcl	Metformin Hcl	39	12
Finasteride	Finasteride	38	suppressed
Ropinirole Hcl	Ropinirole Hcl	38	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	37	suppressed
Nifedipine Er	Nifedipine	37	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	32	suppressed
Promethazine Hcl	Promethazine Hcl	32	suppressed
Varenicline Tartrate	Varenicline Tartrate	32	suppressed
Ibuprofen	Ibuprofen	31	suppressed
Valsartan	Valsartan	31	suppressed
Eliquis	Apixaban	30	suppressed
Methocarbamol	Methocarbamol	30	suppressed
Mirtazapine	Mirtazapine	30	suppressed
Propranolol Hcl Er	Propranolol Hcl	30	suppressed
Ventolin Hfa	Albuterol Sulfate	30	suppressed
Acyclovir	Acyclovir	29	suppressed
Pravastatin Sodium	Pravastatin Sodium	29	suppressed
Metoprolol Succinate	Metoprolol Succinate	28	suppressed
Breo Ellipta	Fluticasone/Vilanterol	27	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	26	suppressed
Buspirone Hcl	Buspirone Hcl	26	suppressed
Hydrocortisone	Hydrocortisone	26	suppressed
Ondansetron Hcl	Ondansetron Hcl	26	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	25	suppressed
Terazosin Hcl	Terazosin Hcl	25	suppressed
Lidocaine	Lidocaine	24	suppressed
Prazosin Hcl	Prazosin Hcl	24	suppressed
Ezetimibe	Ezetimibe	23	suppressed
Prenatal Vitamin Plus Low Iron	Pnv,calcium 72/Iron/Folic Acid	23	suppressed
Meloxicam	Meloxicam	22	suppressed
Spiriva Handihaler	Tiotropium Bromide	22	suppressed
Linzess	Linaclotide	21	suppressed
Naproxen	Naproxen	21	suppressed
Ozempic	Semaglutide	21	suppressed
Citalopram Hbr	Citalopram Hydrobromide	20	suppressed
Diazepam	Diazepam	20	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	20	suppressed
Allopurinol	Allopurinol	19	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	19	suppressed
Bydureon Bcise	Exenatide Microspheres	19	suppressed
Flunisolide	Flunisolide	19	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	19	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	18	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	18	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	17	suppressed
Aripiprazole	Aripiprazole	17	suppressed
Humalog	Insulin Lispro	17	suppressed
Montelukast Sodium	Montelukast Sodium	17	suppressed
Spironolactone	Spironolactone	17	suppressed
Toujeo Max Solostar	Insulin Glargine,hum.Rec.Anlog	17	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	16	suppressed
Spiriva Respimat	Tiotropium Bromide	16	suppressed
Donepezil Hcl	Donepezil Hcl	15	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Topiramate	Topiramate	15	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	15	suppressed
Clopidogrel	Clopidogrel Bisulfate	14	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	14	suppressed
Fenofibrate	Fenofibrate	14	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	14	suppressed
Nexium	Esomeprazole Magnesium	14	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	14	suppressed
Symbicort	Budesonide/Formoterol Fumarate	14	suppressed
Aimovig Autoinjector	Erenumab-Aooe	13	suppressed
Incruse Ellipta	Umeclidinium Bromide	13	suppressed
Lamotrigine	Lamotrigine	13	suppressed
Lamotrigine Er	Lamotrigine	13	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	13	suppressed
Prochlorperazine Maleate	Prochlorperazine Maleate	13	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	13	suppressed
Bupropion Hcl Sr	Bupropion Hcl	12	suppressed
Farxiga	Dapagliflozin Propanediol	12	suppressed
Myrbetriq	Mirabegron	12	suppressed
Potassium Chloride	Potassium Chloride	12	suppressed
Tizanidine Hcl	Tizanidine Hcl	12	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	12	suppressed
Valacyclovir	Valacyclovir Hcl	12	suppressed
Ciclopirox	Ciclopirox	11	suppressed
Insulin Syringe	Syring-Needl,disp,insul,0.3 Ml	11	suppressed
Nurtec Odt	Rimegepant Sulfate	11	suppressed
Praluent Pen	Alirocumab	11	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error